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Abstract
Background: The cyclin D1 proto-oncogene is an important regulator of G1 to S-phase transition
and an important cofactor for several transcription factors in numerous cell types. Studies on
neonatal cardiomyocytes and postmitotic neurons indicate that the activity of cyclin D1 may be
regulated through its cytoplasmic sequestration. We have demonstrated previously, that TSA
induces the ubiquitin-dependent degradation of cyclin D1 in MCF-7 breast cancer cells. Additional
studies were initiated in order to further investigate the effect of TSA on cyclin D1 regulation using
sub-cellular fractionation techniques.
Results: Our studies revealed cyclin D1 to be localized predominantly within the cytoplasmic
fraction of all cell lines tested. These observations were confirmed by confocal microscopy. GSK3β
was found to be localized within both the nucleus and cytoplasm throughout the cell cycle.
Inhibition of GSK3β or CRM1-dependent nuclear export r e s u l t e d  i n  o n l y  m o d e s t  n u c l e a r
accumulation, suggesting that the cytoplasmic localization of cyclin D1 results from the inhibition
of its nuclear import.
Conclusion: We have shown by several different experimental approaches, that cyclin D1 is in
fact a predominantly cytoplasmic protein in mammalian cancer cell lines. Recent studies have shown
that the cytoplasmic sequestration of cyclin D1 prevents apoptosis in neuronal cells. Our results
suggest that cytoplasmic sequestration may additionally serve to regulate cyclin D1 activity in
mammalian cancer cells.
Background
The cyclin D1 proto-oncogene is an important regulator
of G1 to S-phase transition in numerous cell types from
diverse tissues. Binding of cyclin D1 to its kinase partners,
the cyclin dependent kinases 4 and 6 (CDK4\6) results in
the formation of active complexes that phosphorylate the
Retinoblastoma tumor suppressor protein (RB). Hyper-
phosphorylation of RB results in the release of RB-seques-
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terd E2F transcription factors and the subsequent
expression of genes required for entry into S-phase. More
recently, cyclin D1 has also been shown to act a cofactor
for several transcription factors. Initial studies indicated
that cyclin D1 is localized predominantly in the nucleus
of asynchronously growing cells [1]. During cell cycle pro-
gression, protein levels of the cyclin begin to rise early in
G1, prior to its rapid nuclear export and degradation
within the cytoplasm. Interestingly, the nuclear export
and\or degradation of cyclin D1 is required for S-phase
progression as failure to remove the cyclin results in G1
arrest [1,2].
The nuclear export of cyclin D1 has been shown to require
prior phosphorylation on Thr-286 by glycogen synthase
kinase 3β (GSK3β) [3]. This phosphorylation of cyclin D1
was initially thought to regulate its ubiquitin-dependent
degradation. Indeed, mutation of Thr-286 to alanine
resulted in increased stability of the cyclin. Subsequent
studies however, demonstrated that cyclin D1 ubiquityla-
tion and its rapid degradation can occur independently of
GSK3β under certain conditions [4,5]. Nevertheless, it is
still generally believed that cyclin D1 accumulates within
the nucleus during G1, and at the G1-S-phase transition,
GSK3β accumulates in the nucleus and mediates phos-
phorylation, nuclear export and subsequent ubiquitin-
dependent degradation of cyclin D1 in the cytoplasm.
More recently, the serine/threonine kinase Mirk/Dyrk1B
was shown to enhance cyclin D1 degradation by phos-
phorylating Thr288. Mirk activity is restricted to the G0-/
early G1-phase of the cell cycle and may not regulate cyc-
lin D1 in actively cycling cells [6].
Cyclin D1 has also been shown to be an important cofac-
tor for several transcription factors independently of its
CDK activity (reviewed in [7,8]). It is not understood
however, how cells integrate the CDK-dependent and
independent activities of cyclin D1. Cyclin D1 has been
shown to be sequestered in the cytoplasm of neonatal but
not fetal cardiomyocytes [9]. Studies on postmitotic neu-
rons also indicate that the activity of cyclin D1 may be reg-
ulated through its cytoplasmic sequestration [10]. In these
cells, the enforced nuclear localization of cyclin D1
induced apoptosis. The subcellular localization of cyclin
D1 may thus play a role in regulating cellular survival.
The Histone Deacetylase Inhibitor (HDACI) Trichostatin
A (TSA) has been shown to be able to induce cell cycle
arrest, but the exact molecular mechanism involved is not
clear. We have demonstrated previously, that TSA specifi-
cally induces the rapid ubiquitin-dependent degradation
of cyclin D1 in MCF-7 breast cancer cells [11]. Treatment
with TSA also appeared to induce the nuclear exclusion of
wild type but not a Thr-286 mutant GFP-Cyclin D1 in
MCF-7 cells. Additional studies were initiated in order to
further investigate the effect of TSA on cyclin D1 using
sub-cellular fractionation techniques. Interestingly, these
studies revealed cyclin D1 to be localized predominantly
within the cytoplasm of all cell lines and murine tissue
samples examined. Further studies using confocal micros-
copy confirmed the predominantly cytoplasmic localiza-
tion of cyclin D1. GSK3β was found to be localized within
both the nucleus and cytoplasm throughout the cell cycle,
suggesting that the nuclear export of cyclin D1 is a consti-
tutive process. Inhibition of GSK3β or CRM1-dependent
nuclear export resulted in only modest nuclear accumula-
tion, suggesting that the cytoplasmic localization of cyclin
D1 results from the inhibition of its nuclear import. Our
results suggest that the regulation of cyclin D1 activity by
cytoplasmic sequestration may be a common feature in
transformed mammalian cell lines.
Results
Determination of cyclin D1 localization by sub-cellular 
fractionation
We have previously shown that TSA induces cyclin D1
degradation and the apparent nuclear exclusion of ectop-
ically expressed GFP-cyclin D1 in human breast cancer
cell lines. These results coupled with previous findings
suggested that TSA induces cyclin D1 degradation through
mediating its export to the cytoplasm. To test this idea, we
determined by sub-cellular fractionation, the effect of TSA
on endogenous cyclin D1 localization in asynchronous
human cancer cells. Surprisingly, we observed the major-
ity of cyclin D1 is detected in the cytoplasmic fraction of
untreated, asynchronous exponentially growing MCF-7
and MDA-MB231 breast cancer cells (Figures 1A and 1B).
In contrast, the levels of GSK3α and GSK3β were similar
in both the cytoplasmic and nuclear fractions. We con-
firmed efficient cytoplasmic and nuclear fractionation by
localization of Sp1 and Hsp60 (or mitochondrial Hsp70
[mHsp70]) that localized predominantly to the nucleus
and cytoplasm respectively. Culture of MCF-7 breast can-
cer cells with 1 µM TSA for 6 h resulted in a reduction of
cyclin D1 level within both fractions, while treatment
with 50 µM MG132 (a proteasome and cathepsin inhibi-
tor) resulted in increased levels of the cyclin D1 within the
nuclear fraction. We also observed in these studies, that
MG132 abolished the TSA induced loss of cyclin D1 in
both fractions but did not affect the level or localization
of GSK3α and GSK3β (Figure 1A). In contrast, retinoblas-
toma protein (pRb), the cyclin D1-CDK4/6 substrate was
detected largely within the nuclear fraction (Figure 1B).
Similar results were observed in MDA-MB231 cells, with
the exception that co-culture with MG132 also resulted in
reduced GSK3α and GSK3β levels within both fractions
(Figure 1C).
We also wished to determine if similar results could be
observed in non-breast cancer cell lines and tissues.Molecular Cancer 2006, 5:7 http://www.molecular-cancer.com/content/5/1/7
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Effect of TSA on cyclin D1 localization and postranslational regulation Figure 1
Effect of TSA on cyclin D1 localization and postranslational regulation. A. Asynchronously growing MCF-7 cells were treated 
with TSA (1 µM) and MG132 (50 µM) alone or in combination and subjected to subcellular fractionation as described in Meth-
ods. Cell lysates were separated by 4–20 % SDS-PAGE and immunoblot analysis was done using antibodies against Sp1, GSK3 
and cyclin D1. Immunoblots against mitochondrial Sp1 and Hsp70 (mHsp70) served to ensure efficient subcellular fractionation 
and mHsp70 also served to monitor equal gel loading. B. Asynchronously growing MCF-7 cells were subjected to subcellular 
fractionation as described in A. Cell lysates were separated by 4–20 % SDS-PAGE and immunoblot analysis was done using 
antibodies against Sp1, Rb, cyclin D1 and mHsp70. C. Asynchronously growing MDA-MB231 were treated as in A. D. Asyn-
chronously growing SKUT-1B cells were treated as in A. E. Asynchronously growing rat KNRK cells were treated as in A. 
Hsp60 served to ensure efficient subcellular fractionation and also served to monitor equal gel loading.
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Cyclin D1 localization in human cancer cells and murine tissues Figure 2
Cyclin D1 localization in human cancer cells and murine tissues. A. Asynchronously growing U2OS, HeLa and KNRK cells 
were subjected to subcellular fractionation as described in Methods. Cell lysates and insoluble fractions were separated by 4–
20 % SDS-PAGE and immunoblot analysis was done using antibodies against Sp1, GSK3 and cyclin D1. B. Indicated mouse tis-
sues were subjected to subcellular fractionation as described in the Methods section. Cell lysates were separated by 4–20 % 
SDS-PAGE and immunoblot analysis was done using antibodies against cyclin D1. Immunoblots against Rb and Hsp60 served to 
ensure efficient subcellular fractionation. C. Asynchronously growing MCF-7 cells were subjected to proteomic fractionation. 
Cell lysates were separated by 4–20 % SDS-PAGE and immunoblot analysis was done using antibodies against Sp1, GSK3 and 
cyclin D1. Immunoblots against Sp1 and Hsp60 served to ensure efficient subcellular fractionation. D. Asynchronously growing 
MCF-7 cells were subjected to subcellular fractionation using an in-house protocol. Cell lysates were separated by 4–20 % 
SDS-PAGE and immunoblot analysis was done using antibodies against Sp1, GSK3 and cyclin D1.
Sp1
Cyclin D1
Hsp60
C     N
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Effect of cell cycle progression on cyclin D1 localization Figure 3
Effect of cell cycle progression on cyclin D1 localization. A. MCF-7 cells were cultured for 48 h in double stripped phenol red-
free medium containing 100 nm ICI182,780. Cells were treated with fresh medium containing β17-oestrodiol (100 nm) and 
harvested at the indicated time points. Cell lysates were separated by 4–20 % SDS-PAGE and immunoblot analysis was done 
using antibodies against Sp1, GSK3, cyclin D1 and Hsp60. B. MCF-7 cells were left untreated or treated with 1 mM hydroxyu-
rea (HU) for 24 h. HU treated cells were treated with TSA (1 µM) alone or with MG132 (50 µM) for 6 h and treated as in fig-
ure 1A. Immunoblot analysis was done using antibodies against Sp1, GSK3, Skp2, cyclin D1 and Hsp60. C. MDA-MB231 cells 
were treated as in B. D. SKUT-1B cells were treated for 24 h with HU (1 mM) and cell lysates separated by 4–20 % SDS-PAGE. 
Immunoblot analysis was done using antibodies against Sp1, Skp2, cyclin D1 and Hsp60.
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Firstly, we performed similar experiments in the SK-UT-1B
uterine cancer cell line that has been shown previously to
be defective in cyclin D1 degradation [12,13]. As
expected, TSA treatment had little effect on cyclin D1 lev-
els [11] although co-culture with MG132 did result in a
slight increase in cyclin D1 accumulation within the
nuclear fraction. This observation suggested that low lev-
els of cyclin D1 degradation do occur in this cell line (Fig-
ure 1D). The results observed in KNRK transformed rat
kidney fibroblasts were similar to those observed in MDA-
MB231 cells (Figure 1E), with the exception that MG132
that a more pronounced effect on cyclin D1 stability.
Additional experiments in U2OS osteosarcoma and HeLa
cervical cancer cells indicated that cyclin D1 was also
localized predominantly within the cytoplasmic fraction
of these cells. In addition, cyclin D1 was not detected in
the insoluble fraction obtained from these cells following
the separation of the cytoplasmic and nuclear fractions
(Figure 2A). Analysis of the cytoplasmic and nuclear frac-
tions from murine heart, kidney, liver and lung tissue,
similarly demonstrated that the highest levels of cyclin D1
were detectable within the cytoplasmic fraction (Figure
2B). These observations are in agreement with those from
a recent study by De Falco et al., on cyclin D1 localization
in murine tissues [14].
In order to verify these results, we used two additional
protocols to obtain cytoplasmic and nuclear fractions
from MCF-7 cells. Firstly, a second commercially available
kit was used to sequentially isolate cytoplasmic, mem-
brane/organelle, nuclear and cytoskeletal fractions. In
these fractions, the highest levels of cyclin D1 were again
detected in the cytoplasmic fractions and to a lesser extent,
in the membrane/organelle fractions (Figure 2C). Sp1 was
detected solely in the nuclear fraction while equivalent
levels of GSK3α and GSK3β levels were detected in the
cytoplasmic, membrane/organelle and nuclear fractions.
Only GSK3α was detectable in the cytoskeletal fraction,
while the highest levels of Hsp60 were detected in the
cytoplasmic and membrane/organelle fractions. Lastly,
we used an in-house protocol to prepare cytoplasmic and
nuclear fractions from MCF-7 cells. In these experiments,
the highest levels of cyclin D1 were again detected within
the cytoplasmic fraction (Figure 2D). Our data thus
strongly suggested that cyclin D1 is localized predomi-
nantly within the cytoplasm, at least in the various cell
lines and tissues tested.
Effect of cell cycle phase on cyclin D1 levels and sub-
cellular localization
The treatment of MCF-7 cells with the pure antiestrogen
ICI182,780 (100 nM) for 48 h results in reduced cyclin D1
levels and G1 cell cycle arrest in this cell line [15-17].
Treatment of these cells with 17β-oestrodiol following the
removal of ICI182,780, thus results in cell cycle progres-
sion that is accompanied by and dependent on the
increased expression of cyclin D1. We employed this sys-
tem in order to investigate the effect of 17β-oestrodiol on
cyclin D1 accumulation and localization in cytoplasmic
and nuclear fractions from MCF-7 cells. Increased levels of
cyclin D1 were detectable in both fractions at 3 h and were
maximal at ~8 h as previously reported [17]. In our system
however, the highest levels of cyclin D1 were again detect-
able within the cytoplasmic fraction, irrespective of the
time point (Figure 3A).
We next examined the effect of cell cycle arrest at the G1/
S-phase boundary on cyclin D1 localization and levels in
MCF-7, MDA-MB231 and SK-UT-1B cells. Cells were left
untreated or incubated in the presence of 1 mM hydroxy-
urea for 24 h. Under these conditions, >90% of hydroxy-
urea treated cells arrested in late G1 or early S-phase
(results not shown). We observed a marked reduction in
cyclin D1 levels in MCF-7 and MDA-MB231 treated cells
(Figures 3B and 3C). Reduced cyclin D1 levels were
accompanied by increased nuclear levels of the Skp2 F-
box protein that has been previously linked to the ubiqui-
tin-dependent degradation of this cyclin [12,18]. The
degree of cyclin D1 downregulation was clearly propor-
tional to the increase in Skp2 levels (compare Figures 3B
and 3C). The co-culture of hydroxyurea pre-treated cells
with 1 µM TSA for 6 h, lead to further reductions in cyclin
D1 levels in MCF-7 but not MDA-MB231 cells. Co-culture
of both cell lines with TSA and MG132 (50 µM) however,
lead to increased levels of cyclin D1 within both the cyto-
plasmic and nuclear fractions of both cell lines (Figures 3B
and 3C). This observation suggested that the rate of cyclin
D1 degradation is increased in both cell lines under these
conditions. Hydroxyurea did not affect the levels or local-
ization of GSK3α and GSK3β in MCF-7 cells but induced
the downregulation of GSK3β in MDA-MB231 cells. Inter-
estingly, co-culture with hydroxyurea did not result in a
significant reduction of cyclin D1 levels in SK-UT-1B cells,
despite a rise in nuclear Skp2 levels (Figure 3D). Since the
reduction of nuclear cyclin D1 levels has been reported to
be a prerequisite for S-phase progression, our observa-
tions raise interesting questions about how these cells
might progress into S-phase in the absence of cyclin D1
degradation.
Analysis of cyclin D1 localization by confocal microscopy
Based on immunofluorescent studies, cyclin D1 has been
previously localized to the nucleus of asynchronously
growing cells [1]. Our observation that cyclin D1 localiza-
tion was mainly restricted to the cytoplasmic fraction of
the cell lines and tissues examined in this study was there-
fore surprising. Indeed, experiments from our own labo-
ratory using an FITC-conjugated anti-cyclin D1 antibody
also suggested a predominantly nuclear localization for
this cyclin (Figure 4A). We observed however, that inMolecular Cancer 2006, 5:7 http://www.molecular-cancer.com/content/5/1/7
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Determination of cyclin D1 localization by confocal microscopy Figure 4
Determination of cyclin D1 localization by confocal microscopy. A. MCF-7 cells were allowed to attach to coverslips overnight 
and were then treated with or without MG132 (50 uM) for 6 h. Cells were fixed in ice cold methanol, washed and stained 
overnight with an FITC conjugated anti- cyclin D1 antibody, counterstained with DAPI and examined by fluorescence micros-
copy. B. MCF-7 cells grown on coverslips were transfected with wild type or T286A mutant GFP-cyclin D1 and incubated 
overnight to allow for expression of the recombinant protein. Cells were fixed in ice cold methanol, counterstained with DAPI 
and examined by direct fluorescence microscopy. C. MCF-7 cells were left untransfected or transfected with the indicated 
GFP-cyclin D1 constructs. Cell lysates were separated by 4–20 % SDS-PAGE. Immunoblot analysis was done using antibodies 
against Sp1, GFP and Hsp60. D. MCF-7 cells were grown on coverslips and transfected with wild type GFP-cyclin D1. Cells 
were fixed in ice cold methanol and examined by confocal microscopy. E. MCF-7 cells were allowed to attach to coverslips 
overnight and were then fixed in ice cold methanol, washed and stained overnight with an FITC conjugated anti- cyclin D1 anti-
body. Cells were subsequently examined by confocal microscopy.Molecular Cancer 2006, 5:7 http://www.molecular-cancer.com/content/5/1/7
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Cytoplasmic sequestration of cyclin D1 in human cancer cell lines Figure 5
Cytoplasmic sequestration of cyclin D1 in human cancer cell lines. A. Asynchronously growing MCF-7 cells were treated with 
cycloheximide (Chx) (50 µM) alone and together with MG132 (50 µM) or LMB 10 ng/ml as indicated. Cell lysates were sepa-
rated by 4–20 % SDS-PAGE and immunoblot analysis was done using antibodies against Sp1, GSK3, cyclin D1, p21 and Hsp60. 
B. Asynchronously growing SKUT-1B cell were treated as in A. C. MCF-7 cells were treated for 24 h with the GSK3-specific 
inhibitor SB216763. Cell lysates were separated by 4–20 % SDS-PAGE and immunoblot analysis was done using antibodies 
against Sp1, cyclin D1 and mHsp70.
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MCF-7 cells transiently expressing GFP-Cyclin D1, the
recombinant protein appeared to be localized to both the
cytoplasm and nucleus when examined by direct immun-
ofluorescence microscopy (Figure 4B). When these cells
were subjected to sub-cellular fractionation and analysed
by immunoblot analysis with a monoclonal antibody
against GFP, the recombinant protein was again detected
predominantly within the cytoplasmic fraction (Figure
4C). Single or combined mutations of Thr-286 or Thr-288
to alanine resulted in only a slight increase of the recom-
binant protein within the nuclear fraction. These observa-
tions strongly suggested that the apparent nuclear
localization of cyclin D1 as determined by indirect
immunofluorescence microscopy may be an artefact of
this particular technique. We thus decided to examine the
localization of both endogenous and transiently
expressed GFP-Cyclin D1 in MCF-7 cells by confocal
microscopy. These experiments confirmed that cyclin D1
does not indeed, localize predominantly within the
nucleus of mammalian cells (Figures 4D and 4E).
Combined proteasome and CRM1 inhibition does not 
result in the nuclear localization of cyclin D1
The inhibition of protein synthesis by cycloheximide
results in rapid disappearance cyclin D1 in several cell
lines [19]. According to the current model for cyclin D1
posttranslational regulation and our data presented
above, cytoplasmic cyclin D1 would need to rapidly enter
the nucleus, where its phosphorylation and subsequent
ubiquitylation would target it for nuclear export and deg-
radation within the cytoplasm [12,20]. We thus wished to
determine, if we could induce the predominant nuclear
localization of cyclin D1 in cycloheximide treated cells by
simultaneously inhibiting nuclear export and degradation
of the cyclin. Co-culture of asynchronous MCF-7 cell pop-
ulations with 50 µM cycloheximide for 2 h resulted in the
loss of cyclin D1 in both fractions (Figure 5A). This effect
could be abolished by MG132 (50 µM), leading to the sta-
bilization of the cyclin in both fractions. Co-culture of
cycloheximide treated cells with MG132 and LMB (an
inhibitor of CRM1), lead to further increases in the level
of cyclin D1 within both fractions but not in the predom-
inant nuclear localization of the protein. Similar treat-
ments in SK-UT-1B cells did not affect the levels or
localization of cyclin D1 (Figure 5B). Inhibition of GSK3
activity by SB216763 resulted in modest nuclear accumu-
lation of cyclin D1 in MCF-7 cells (Figure 5C). Our data
thus clearly demonstrates, that i) cyclin D1 localizes pre-
dominantly to the cytoplasm in all cell lines and tissues
examined and ii) that the nuclear exclusion/cytoplasmic
sequestration of the cyclin as opposed to its accumulation
appears to be the rule. Cyclin D1 downregulation has
been shown to be a prerequisite for S-phase progression
[2]. Our findings thus offer a novel explanation for the
continued proliferation of cells that are either defective in
cyclin D1 downregulation [12,13], or express variants
lacking the C-terminal Thr-286 residue required for
nuclear export and degradation within the cytoplasm
[21]. The failure of cyclin D1 to relocalize to the nucleus
when both its degradation and nuclear export are inhib-
ited, suggests that the nuclear import of this protein is
inhibited in these cell lines.
Discussion
Here we show that cyclin D1 is localized predominantly
within the cytoplasm of mammalian cancer cells. Recent
studies in our laboratory have demonstrated that TSA
induces the rapid degradation of cyclin D1 in MCF-7
breast cancer cells and to a lesser extent in several other
cell lines [11]. In these studies, TSA induced the apparent
nuclear exclusion of wild type GFP-Cyclin D1 but not a
Thr-286 mutant in MCF-7 cells transiently expressing
these proteins. We used sub-cellular fractionation kits in
order to determine if TSA would have a similar effect on
the localization of endogenous cyclin D1. Early studies
suggested that cyclin D1 localized predominantly to the
nucleus of asynchronously growing embryonic lung
fibroblasts [1]. Later studies in cardiomyocytes and neuro-
nal cells demonstrated the predominantly cytoplasmic
localization in these cells [9,10]. Interestingly, Tamamori-
Adachi  et al., [9] observed that although ectopically
expressed cyclin D1 accumulated to a greater degree in
fetal cardiomyocytes, this localization was not predomi-
nantly nuclear. The results presented here indicate that the
highest levels of cyclin D1 are consistently detectable
within the cytoplasmic fraction, irrespective of the cell
cycle phase, or cell line examined. Furthermore, equal lev-
els of GSK3β were detectable in both cytoplasmic and
nuclear fractions throughout the cell cycle.
The mechanisms that regulate the nuclear exclusion of
cyclin D1 remain unclear. Inhibition of CRM1-dependent
nuclear export by LMB has been shown previously, to
induce the nuclear localization of cyclin D1 in mouse
embryonic fibroblasts [20]. Our results show however,
that the inhibition of GSK3β or CRM1-dependent nuclear
export does not result in the effective nuclear accumula-
tion of cyclin D1 in mammalian cancer cell lines. In our
experiments, inhibition of GSK3β or CRM1 activity
resulted in the modest nuclear accumulation of cyclin D1.
GSK3β may thus play a role in regulating the nuclear lev-
els of cyclin D1. When G1 arrested MCF-7 cells were
induced to re-enter the cell cycle, cyclin D1 accumulated
mainly within the cytoplasmic fraction and to a lesser
extent within the nuclear fraction. In addition, the com-
bined inhibition of proteasomal degradation and nuclear
export inhibition in cycloheximide treated cells resulted
in only a modest nuclear accumulation of cyclin D1 (Fig-
ure 5). These findings suggest that the impaired nuclearMolecular Cancer 2006, 5:7 http://www.molecular-cancer.com/content/5/1/7
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import of cyclin D1 results in its cytoplasmic sequestra-
tion in these cells lines.
In our hands, indirect immunofluorescence studies with
an FITC-conjugated anti-cyclin D1 antibody suggested a
predominantly nuclear localization for the cyclin. This
antibody belongs to the same clone that suggests a pre-
dominantly cytoplasmic localization of cyclin D1 in
immunoblot analyses of fractionated cell lysates. In con-
trast, transiently expressed wild type or Thr-286 mutated
GFP-Cyclin D1 exhibited an even nucleo-cytoplasmic
localization when examined by direct fluorescence micro-
scopy. Westernblotting analyses of cytoplasmic and
nuclear extracts however, indicated that both the endog-
enous and recombinant proteins are localized predomi-
nantly within the cytoplasm. Confocal microscopy studies
on cells expressing GFP-Cyclin D1 or endogenous cyclin
D1 confirmed the predominantly cytoplasmic localiza-
tion of these proteins. Our observations suggest that the
apparent nuclear localization of cyclin D1 (as determined
by indirect immunofluorescence microscopy) is an arte-
fact of the particular technique.
Conclusion
Early studies on cyclin D1 localization have been based
on indirect immunofluorescence studies in embryonic.
We have shown by several different experimental
approaches, that cyclin D1 is in fact a predominantly cyto-
plasmic protein in mammalian cancer cell lines. Our find-
ings also indicate that the cytoplasmic sequestration of
cyclin D1 may result from the inhibition of its nuclear
import. The important role that cyclin D1 plays in both
the normal and pathological setting has thus ensured that
this protein remains the active focus of several research
groups. Therefore, the development of accurate models to
describe the regulation of cyclin D1 under both normal
and pathological conditions is not only highly desirable
but extremely important. Our findings provide evidence
for the regulation of cyclin D1 activity by cytoplasmic
sequestration in several mammalian cancer cell lines and
murine tissues. Recent studies have shown that the cyto-
plasmic sequestration of cyclin D1 prevents apoptosis in
neuronal cells [10,22,23]. Our results suggest that cyto-
plasmic sequestration may additionally serve to regulate
cyclin D1 activity in mammalian cancer cells.
Methods
Reagents
Carbobenzoxy-leucyl-leucyl-leucinal (Z-LLL-CHO,
MG132) (Calbiochem, VWR International Ltd., Lutter-
worth, United Kingdom) was dissolved in DMSO at the
indicated concentrations and stored at -20°C. Stock solu-
tions of TSA, 17β-oestrodiol and cycloheximide in etha-
nol and leptomycin B in 70% (v/v) methanol (Sigma-
Aldrich; Dorset, united Kingdom) were stored at -20°C.
The GSK3-specific inhibitor SB216763 (Tocris Bioscience,
Avonmouth, United Kingdom) was dissolved in DMSO
and stored at -20°C. Antibodies to cyclin D1, actin, Sp1,
Skp2, p21 and GFP (Santa Cruz Biotechnology, santa
Cruz, CA), GSK3 (Upstate Biotechnology, Dundee,
United Kingdom), Hsp60, mHsp70 (Abcam, Cambridge,
United Kingdom), and β-Catenin (Transduction Labora-
tories, BD Biosciences Ltd., Oxford, United Kingdom,
Santa Cruz Biotechnology) were used.
Cell culture
MCF-7, MDa-MB231, HeLa, SK-UT-1B cells, KNRK and
U2OS cells (American Type Culture Collection, Rockville,
MD) were cultured in DMEM supplemented with 10% (v/
v) fetal calf serum, 2 mM L-glutamine, 100 units/ml pen-
icillin and 100 µg/ml streptomycin at 37°C in humidified
5% CO2.
Sub-cellular fractionation
Cytoplasmic and nuclear fractions were prepared from
asynchronously growing cells or fresh murine tissue sam-
ples using an NE-PER® Nuclear-cytoplasmic kit (Perbio,
Erembodegem, Belgium) according to the manufacturer's
instructions. Alternatively, cytoplasmic, membrane/
organelle, nuclear and cytoskeletal fractions were pre-
pared using a ProteoExtract® Subcellular Proteome Extrac-
tion Kit (Calbiochem, VWR International Ltd.,
Lutterworth, United Kingdom) according to the manufac-
turer's instructions. The purity of each fraction was ana-
lyzed by immunoblotting using antibodies against Sp1
and Hsp60 (or mitochondrial Hsp70 [mHsp70]).
Transfection and immunoblot analysis
Fugene 6 transfection reagent (Roche Diagnostics Ltd, East
Sussex, United Kingdom) was used for DNA plasmind
transfection. asynchronous cell populations at a density of
50–60% in 6-well plates or on coverslips were transfected
with 1–2 µg of plasmid DNA, following the formation of
lipid-DNA complexes for 20 min at room temperature in
Optimem I medium (Invitrogen Ltd., Paisley, United
Kingdom). Complexes were added directly to cells grow-
ing in 2 ml DMEM and incubated for 5 h followed by
washing with PBS buffer and the addition of fresh
medium. Cells were used 24 h after transfection and the
recombinant proteins detected by immunoblotting, or by
fluorescence microscopy as previously described [11].
Confocal microscopy
MCF-7 cells were grown on sterile glass coverslips in 24-
well plates to 30% confluence in RPMI media before
being washed three times in PBS. Cells were fixed in meth-
anol at -20°C for ten minutes. Coverslips were washed a
further three times in PBS and treated with 10% whole
goat serum (Santa Cruz) for thirty minutes. Antibodies to
FITC-conjugated anti-Cyclin D1 (Santa Cruz) (1:50 dilu-Molecular Cancer 2006, 5:7 http://www.molecular-cancer.com/content/5/1/7
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tion) were applied in L15 (Sigma-Aldrich) medium over-
night. Cells were washed five times in PBS, mounted on
glass slides with Vectorshield containing DAPI (Vector
Laboratories Inc.) and visualised on a Zeiss Meta 512 con-
focal microscope.
Abbreviations
TSA- trichostatin A, Z-LLL-CHO- carbobenzoxy-leucyl-
leucyl-leucinal (MG132), LMB- Leptomycin B, DMSO-
dimethyl sulphoxide, DMEM- Dulbecco's modified eagle
medium, DAPI- 4', 6'- diamidino-2-phenylindole dihy-
drochloride, PBS- phosphate buffered saline, RT-PCR-
reverse transcription- polymerase chain reaction, FITC-
fluorescein isothiocyanate, GSK3α- glycogen synthase 3
alpha, GSK3β- glycogen synthase 3 beta, GFP- Green fluo-
rescent protein, Hsp60- Heat shock protein 60, mHsp70-
mitochondrial Heat shock protein 70, Rb- retinoblastoma
protein
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